Treatment of Acute Severe Ulcerative Colitis
Intravenous corticosteroids (prednisolone or equivalent) are the first-line treatment for acute severe ulcerative colitis, and if there is no adequate response within 2 weeks, infliximab should be initiated as rescue therapy over cyclosporine. 1
Initial Management: IV Corticosteroids
Start with intravenous prednisolone (or equivalent corticosteroid) immediately upon hospitalization 1. This remains the cornerstone first-line therapy despite one-third of patients failing to respond 2, 3. The historical evidence supporting corticosteroids showed 41.3% remission rates at 6 weeks with cortisone (equivalent to prednisolone dosing) 1.
Critical Decision Point: Assessing Steroid Response
Evaluate response within 2 weeks - this is your key decision window 1. Do not wait longer, as delayed intervention increases morbidity and mortality risk 3.
Rescue Therapy: When Steroids Fail
Infliximab as Preferred Rescue Agent
Infliximab is superior to cyclosporine for rescue therapy based on the most recent meta-analysis 4:
- 44% lower risk of colectomy at discharge (RR 0.56,95% CI 0.38-0.81)
- 33% lower risk of colectomy at 3 months (RR 0.67,95% CI 0.48-0.92)
- 44% lower risk of colectomy at 12 months (RR 0.56,95% CI 0.42-0.75)
Important caveat: Infliximab carries 2.4-fold higher infection risk compared to cyclosporine (RR 2.38,95% CI 1.27-4.47) 4, so monitor closely for infectious complications.
Dosing Considerations for Infliximab
Consider accelerated or intensified dosing regimens in patients with:
- High inflammatory burden
- Hypoalbuminemia
- Severe disease at presentation 5
While evidence for accelerated dosing shows mixed results 2, it appears sensible in high-risk patients with low albumin and high disease burden 2.
Alternative Rescue Options
Cyclosporine remains an option when:
- Patient has prior infliximab exposure 2
- Infliximab is contraindicated
- Local availability/reimbursement favors cyclosporine
Tacrolimus can also be used as rescue therapy 3, though less commonly than infliximab or cyclosporine.
Emerging Therapies
JAK Inhibitors
Tofacitinib combined with IV corticosteroids from admission improves short-term clinical response at day 7 4, though no difference in 3-month colectomy rates has been demonstrated yet 4.
Upadacitinib shows promise as salvage therapy when IV corticosteroids and infliximab (standard or intensified) fail 5, but requires more robust trial data before routine recommendation.
When to Consider Surgery
Proceed to colectomy if:
- No adequate response to rescue therapy (infliximab or cyclosporine)
- Clinical deterioration despite medical therapy
- Development of complications (toxic megacolon, perforation)
Timely surgical decision-making is critical - do not delay colectomy in patients failing medical rescue therapy, as this compromises patient safety 3.
Key Clinical Pitfalls to Avoid
Waiting too long to escalate: The 2-week window for steroid response assessment is crucial - do not extend this timeline 1
Underestimating infection risk: Infliximab increases infection risk 2.4-fold compared to cyclosporine 4 - maintain high vigilance for infectious complications
Using corticosteroids for maintenance: Never continue corticosteroids long-term after achieving remission 1 - transition to appropriate maintenance therapy
Delaying surgical consultation: Involve colorectal surgery early in the hospital course; multidisciplinary teams improve outcomes 3
Ignoring albumin levels: Low albumin predicts poor infliximab response and may warrant intensified dosing 5, 2
Maintenance After Acute Episode
Once remission is achieved, continue with the agent successful in achieving induction (typically infliximab if used as rescue) 1. Consider adding purine analogues alongside infliximab therapy 1. The treatment goal has shifted from clinical response to achieving complete biochemical, endoscopic, and histological remission 1.